Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Luye Pharma's Rivastigmine Transdermal Patch Receives Market Approval in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Luye Pharma"},{"company":"Luye Pharma","sponsor":"Towa Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Luye Pharma and Towa Pharmaceutical Enter Collaboration to Develop and Commercialize Rivastigmine Multi-Day Transdermal Patch in Japan","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Luye Pharma"},{"company":"Luye Pharma","sponsor":"Luye Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Italfarmaco Group Enters Into an Agreement with Luye Pharma to Commercialize Rivastigmine Multi-Day Transdermal Patch","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Luye Pharma"},{"company":"Bened Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Psychobiotic PS128 Registration, Health Claims Approved in Thailand, Canada","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Bened Biomedical"}]

Bened Biomedical

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Psychobiotic PS128 Registration, Health Claims Approved in Thailand, Canada

Details:

Lactobacillus plantarum PS128 probiotic is natural, safe way to boost mental and neural health, works from within gut to balance levels of dopamine, serotonin, and other molecules.

Lead Product(s): Lactobacillus Plantarum

Therapeutic Area: Neurology Product Name: PS128

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 06, 2022

ASK
US

Upload
your Pipeline Activity

Luye Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Italfarmaco Group Enters Into an Agreement with Luye Pharma to Commercialize Rivastigmine Multi-Day Transdermal Patch

Details:

Under the terms of the agreement, Italfarmaco gains the exclusive rights to commercialize Rivastigmine MD in Germany, Italy, Portugal and Greece. Italfarmaco will also have a preferred right to market Rivastigmine MD in Chile and Vietnam.

Lead Product(s): Rivastigmine

Therapeutic Area: Neurology Product Name: Rivastigmine MD

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Luye Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 16, 2021

ASK
US

Upload
your Pipeline Activity

Luye Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Luye Pharma and Towa Pharmaceutical Enter Collaboration to Develop and Commercialize Rivastigmine Multi-Day Transdermal Patch in Japan

Details:

According to the agreement, Luye Pharma has granted Towa the exclusive rights to develop and commercialize Rivastigmine MD in Japan.

Lead Product(s): Rivastigmine

Therapeutic Area: Neurology Product Name: Rivastigmine MD

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Towa Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 18, 2021

ASK
US

Upload
your Pipeline Activity

Luye Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Luye Pharma's Rivastigmine Transdermal Patch Receives Market Approval in China

Details:

It is the first transdermal patch product approved for marketing under China CDE’s quality and efficacy consistency evaluation. Rivastigmine Transdermal Patch works by delivering medication through the epidermis and dermis to the dermal layer.

Lead Product(s): Rivastigmine

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 09, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY